---
title: "A Complete Roadmap for US Biotechs Entering the EU/UK Market"
description: "US biotech ready to expand into Europe? This whitepaper walks you through the four critical stages of EU/UK market entry, from choosing the right regulatory pathway to building operational readiness on the ground."
url: https://qbdgroup.com/zh-cn/downloads/roadmap-us-biotechs-eu-uk-market
type: "White paper"
language: zh-cn
published: 2026-06-08
author: "Angeles Escartí-Nebot"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"A Complete Roadmap for US Biotechs Entering the EU/UK Market\", https://qbdgroup.com/zh-cn/downloads/roadmap-us-biotechs-eu-uk-market"
---
# A Complete Roadmap for US Biotechs Entering the EU/UK Market
> US biotech ready to expand into Europe? This whitepaper walks you through the four critical stages of EU/UK market entry, from choosing the right regulatory pathway to building operational readiness on the ground.

## About this whitepaper

Breaking into the EU/UK market is one of the biggest steps a US biotech can take, and one of the most misunderstood. Many companies assume their **FDA-approved data package** and development approach will transfer over with minimal adjustment. In practice, that assumption leads to delays, costly rework, and regulatory risk that could have been avoided.

This whitepaper, written by **Angeles Escartí-Nebot**, lays out a clear, practical roadmap for US biotechs at any stage of European expansion. It covers the **structural differences** between the US and EU regulatory systems, the most common pitfalls, and the strategic decisions that determine whether market entry runs smoothly or gets derailed.

Whether you''re evaluating your **first EU submission** or trying to get ahead of operational requirements like **QP oversight** and **pharmacovigilance**, this guide gives you the framework to plan with confidence.

## What you''ll learn

- Why **EU market entry is not a continuation of your FDA pathway**, and what that means for your development program
- How to choose between the **EMA centralised procedure** and **national routes**, and when that decision can make or break your timeline
- What FDA-ready data packages typically miss when it comes to **EU CMC expectations**, clinical design, and dossier formats
- Why the **UK can be a smart, lower-friction entry point** before tackling the broader EU framework
- What **operational infrastructure** you need in place before approval, including **pharmacovigilance systems, QP oversight, and MAH setup**, and why leaving this to post-approval is a risk you don''t want to take
---
Source: https://qbdgroup.com/zh-cn/downloads/roadmap-us-biotechs-eu-uk-market — © QbD Group. Quote freely with attribution and a link back.